Using a composite TIS signature involving p21WAF1/Cip1+, H3K9me3+, and lamin B1 loss, ∼41% of breast cancer samples with an incomplete or partial response to neoadjuvant chemotherapy showed marker expression consistent with a senescence-like phenotype (129). This evidence concerns the gene LMNB1 and breast carcinoma.